ZNTL - Zentalis Pharmaceuticals, Inc.

4.05
-0.200   -4.938%

Share volume: 1,180,353
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$4.25
-0.20
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 23%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.76%
1 Month
89.25%
3 Months
61.35%
6 Months
164.71%
1 Year
195.62%
2 Year
-64.54%
Key data
Stock price
$4.05
P/E Ratio 
N/A
DAY RANGE
$3.93 - $4.34
EPS 
-$2.21
52 WEEK RANGE
$1.13 - $6.95
52 WEEK CHANGE
$185.21
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
70.931 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
1.76
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,454,402
AVERAGE 30 VOLUME 
$4,230,856
Company detail
CEO: Kimberly L. Blackwell
Region: US
Website: zentalis.com
Employees: 160
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trials. The company has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC, GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd.

Recent news